SOX2 and melanoma: Silencing of BRD4, as well as its pharmacological depletion with MZ1 or catalytic inhibition through JQ1, prevented SOX2-binding to GLI1 promoter (Fig. 2B, C), without altering SOX2 expression in melanoma cells (Supplementary Fig. 6).